Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of STAT3 inhibitors, has initiated dosing of the first patients in its ongoing REVERTIPF trial.

This article summarized the latest R&D progress of Disitamab Vedotin, the Mechanism of Action for Disitamab Vedotin, and the drug target R&D trends for Disitamab Vedotin.

Proton pumps are enzymes found in the stomach lining that play a crucial role in the production of gastric acid.

Founded in 1994, Exelixis, Inc. is a biotechnology company in California focused on the anti-tumor field that has commercialized new drug products.

Genentech announced today that the Phase III ALINA study assessing Alecensa® (alectinib) has achieved its primary endpoint of disease-free survival (DFS) during a pre-determined interim analysis.

Brotizolam is a small molecule drug that targets the GABAA receptor in the nervous system.

JAK inhibitors can inhibit JAK kinases, block the JAK-STAT signaling pathway, and have great therapeutic potential for a variety of diseases including tumors, immune & inflammation···

Amgen Inc. is a biotechnology company dedicated to providing biological therapeutics to patients with serious diseases by discovering, developing, manufacturing, and delivering innovative human therapies.

Harbour BioMed declared that the U.S. FDA has given the go-ahead for the IND application, permitting the initiation of clinical studies for its inaugural Antibody Drug Conjugate (ADC) project, HBM9033.

This article summarized the latest R&D progress of Bromocriptine Mesylate, the Mechanism of Action for Bromocriptine Mesylate, and the drug target R&D trends for Bromocriptine Mesylate.

Monoamine Oxidase(MAO) is a naturally existing oxidase in the human body, located on the outer membrane of mitochondria.

Alkermes Plc is a biopharmaceutical company focused on central nervous system (CNS) disorders such as schizophrenia, depression, addiction, and multiple sclerosis.